. 2012 Feb 25;3(1):12–16. doi: 10.1007/s13193-012-0138-2

Table 3.

Clinicopathological characterisitics of patients who developed Recurrence

S.No.	Age (Years)	Menopaus al staus	Treatment given	Type of cancer, Grade	Initial stage	Adjuvant treatment	Recurrence	DFS (Months)	OS (Months)
1.	48	Pre	MRM	IDC, 3	T3N1M0	CT + RT	LR	12	17
2.	55	Post	MRM	IDC, 3	T2N2aM0^a	CT + RT	LR	3	5
3.	48	Post	NACT➔MRM	IDC, 3	T2N3aM0	CT + RT	LR + SCLN + Brain metastases	6	10 (Expired)
4.	28	Pre	NACT➔MRM	IDC, 3	T4bN1M0	CT + RT	LR + Bone metastases	9	11 (Expired)
5.	45	Pre	MRM	IDC, 3	T2N1M0^a	CT + RT	LR + SCLN	58	70
6.	54	Post	NACT➔MRM	IDC, 2	T4bN2aM0	CT + RT	LR + Bone metastases	12	14
7.	40	Pre	NACT➔MRM	IDC,3	T3N1M0	CT + RT	LR + SCLN	10	14

^a- Post surgery outside referred to us, Pre Premenopausal, Post Postmenopausal, NACT Neoadjuvant chemotherapy, MRM Modified radical mastectomy, CT Chemotherapy, RT Radiotherapy, LR local recurrence, SCLN supraclavicular Lymph node metastases, IDC Invasive ductal cancer, DFS Disease free survival, OS Overall survival